Blog

Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?

Thor Halfdanarson/mayoclinic.org

May 25, 2025, 05:33

Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?

Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X:

“Lu-177 DOTATATE PRRT in patients with NETs and extensive bone metastases. Is it effective and is it safe?

It looks like the answer is yes to both and indeed, we use it frequently under such circumstances. Skeletal related events were 20%…”

Title: Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience

Authors: Kunal Ramesh Chandekar, Swayamjeet Satapathy, Sanjana Ballal, Madhav Prasad Yadav, Shubha Gadde Ravindra, Sameer Rastogi, Ranjit Kumar Sahoo, Chandrasekhar Bal

You can read the Full Article on Journal of Nuclear Medicine.

Thor Halfdanarson: Is it Effective and Safe to Use Lu-177 DOTATATE PRRT in Patients With NETs and Extensive Bone Metastases?

More posts featuring Thor Halfdanarson.

cancer Chandrasekhar Bal Kunal Ramesh Chandekar Madhav Prasad Yadav NETs OncoDaily Oncology Ranjit Kumar Sahoo Sameer Rastogi Sanjana Ballal Shubha Gadde Ravindra Swayamjeet Satapathy Thor Halfdanarson

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology